Completed
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT02362035
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, CLL, +47 more
- Locations
-
- Research Site Tucson, Arizona, United States
- Research Site Los Angeles, California, United States
- Research Site Denver, Colorado, United States
- Research Site Washington D.C., District of Columbia, United States